文献速递肝病消化道肿瘤与早癌

长期二甲双胍使用或改善伴桥接纤维化或代偿性肝硬化的糖尿病NASH患者临床结局

Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
PubMed 文献 · Aliment Pharmacol Ther · 2019-06-03

该回顾性研究纳入191例经活检证实为非酒精性脂肪性肝炎(NASH)且伴桥接纤维化或代偿性肝硬化的糖尿病患者,其中110例使用二甲双胍,81例从未使用。随访期间,二甲双胍使用与较低的全因死亡或移植风险(HR 0.42;95%CI 0.24-0.74,P=0.003)以及较低的肝细胞癌风险(sHR 0.25;95%CI 0.11-0.58,P=0.001)相关。

要点

  • 长期二甲双胍使用与NASH合并晚期纤维化糖尿病患者较低的全因死亡或移植风险相关。
  • 二甲双胍使用与较低的肝细胞癌风险相关。
  • 未观察到肝毒性或乳酸酸中毒事件。

核心结论

  • 长期二甲双胍使用与伴桥接纤维化或代偿性肝硬化的糖尿病NASH患者全因死亡/移植及肝细胞癌风险降低相关。

研究设计与样本

  • 回顾性识别2004年10月至2016年1月印第安纳大学医学中心191例经活检证实NASH且伴桥接纤维化或代偿性肝硬化的糖尿病患者,其中110例为二甲双胍使用者,81例从未使用。

主要发现

  • 二甲双胍使用者中肝硬化占85%,非使用者中占88%。
  • 二甲双胍剂量≥1 g/d者104/110例,中位使用时长6年(95%CI:4.4-7.9)。
  • 二甲双胍使用者平均随访6.92年,非使用者6.80年。
  • 随访期间28例发生肝细胞癌(使用者7例,非使用者21例),52例死亡(使用者7例,非使用者24例)或接受移植(使用者13例,非使用者13例)。
  • 二甲双胍使用与较低的全因死亡或移植风险相关(HR 0.42;95%CI 0.24-0.74,P=0.003),与较低的肝细胞癌风险相关(sHR 0.25;95%CI 0.11-0.58,P=0.001),经倾向评分及协变量调整后仍独立相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metformin may protect against hepatocellular carcinoma and mortality among patients with type 2 diabetes. AIM: To investigate whether long-term use of metformin improves survival and reduces liver-related outcomes among patients with type 2 diabetes and non-alcoholic steatohepatitis. METHODS: A total of 191 diabetic patients with biopsy-proven non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis were retrospectively identified at Indiana University Medical Center between October 2004 and January 2016. Of them, 110 were users and 81 never-users of metformin. Primary outcomes were transplant-free survival, development of hepatocellular carcinoma or a first event of hepatic decompensation. RESULTS: Cirrhosis was present in 85% of metformin users and 88% of nonusers. Metformin dose was greater than or equal to 1 g/d in 104 out of 110 users and its median duration of use was 6 (95% CI: 4.4-7.9) years. The mean follow-up was 6.92 and 6.80 years for metformin users and non-users, respectively. During follow-up, 28 patients developed hepatocellular carcinoma (metformin users: 7, nonusers: 21), and 52 died (metformin users: 7, nonusers: 24) or were transplanted (metformin users: 13, non-users: 13). Metformin use was associated with lower risk of overall mortality or transplant (HR: 0.42; 95% CI: 0.24-0.74, P = 0.003) and hepatocellular carcinoma (sHR: 0.25; 95% CI: 0.11-0.58, P = 0.001), and remained independently associated with both outcomes after propensity-score and covariate-adjusted analyses. No instances of hepatotoxicity or lactic acidosis were observed. CONCLUSION: Our study demonstrated an association between long-term metformin use and reduced the risk of all-cause mortality/transplant and hepatocellular carcinoma in diabetics with non-alcoholic steatohepatitis and advanced fibrosis.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vilar-Gomez E, Vuppalanchi R, Desai AP, et al. Long-term metformin use may improve clinical outcomes in diabetic patients with non-alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 31157422. doi:10.1111/apt.15331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。